Qiagen NV Announces $750 Million Non-US Offering of Net Share Settled Convertible Bonds

Reuters
Aug 28
Qiagen NV Announces $750 Million Non-US Offering of Net Share Settled Convertible Bonds

QIAGEN N.V., a biotechnology company, has announced a non-U.S. offering of net share settled convertible bonds. The senior, unsecured bonds are set to mature in 2032 and will be issued in minimum denominations of USD 200,000, with an aggregate volume of USD 750 million. The bonds are convertible in part into ordinary shares of the company. QIAGEN plans to use the net proceeds from this issuance for general corporate purposes, including refinancing existing debt. The expected settlement date for the bonds is September 4, 2025, and they will be admitted to trading on the Open Market segment of the Frankfurt Stock Exchange. The bonds will not be offered in the United States, Canada, Australia, Japan, South Africa, or any jurisdiction where such an offering would be unlawful.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2189772_en), on August 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10